Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler (200 Microgram) in Adult and Adolescent Patients With Asthma

X
Trial Profile

A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler (200 Microgram) in Adult and Adolescent Patients With Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol/mometasone (Primary) ; Mometasone
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms QUARTZ
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Jan 2022 A review outlining the unique strategy used in the accelerated development of IND/GLY/MF that combined various approaches comprising data from 3 study (QUARTZ and PALLADIUM evaluated IND/MF while IRIDIUM and ARGON evaluated IND/GLY/MF) published in the Advances in Therapy
    • 27 Jan 2021 Results of a pooled analysis assessing cardiovascular safety from four clinical studies: PALLADIUM, IRIDIUM, ARGON and QUARTZ published in the Respiratory Medicine
    • 01 Jan 2020 Results published in the Respiratory Medicine
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top